Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14675271 | 0.81 | ADRB2 (0.45) | KDM4EALDH1A1GAAHPGDL3MBTL1 | |
| SCHEMBL2656380 | 0.81 | CYP1A2 (0.31) | KDM4EALDH1A1GAAHPGDL3MBTL1 | |
| SCHEMBL21168751 | 0.80 | — | — | |
| SCHEMBL28889526 | 0.77 | ALDH1A1 (0.37) | KDM4EALDH1A1GAAHPGDCTSS | |
| SCHEMBL14675556 | 0.74 | XDH (0.45) | KDM4EALDH1A1GAAHPGDL3MBTL1 | |
| SCHEMBL14675564 | 0.72 | ESR2 (0.43) | — | |
| SCHEMBL14675623 | 0.70 | CYP2A6 (0.33) | ALDH1A1 | |
| SCHEMBL30084929 | 0.69 | MAPT (0.41) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL28920164 | 0.69 | MAPT (0.41) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL16874395 | 0.69 | THRB (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739609-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2019-07-17 | — | — | EP | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2017-05-11 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-9586891-B2 | Estrogen receptor ligands | KARO PHARMA AB (SE) | 2017-03-07 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO PHARMA AB (SE) | 2014-10-30 | — | — | US | disclosed |
| EP-2739609-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013017654-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128434-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | KDM4E 443/4885ALDH1A1 1517/4885GAA 4304/4885 |
| US-20140323518-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | KDM4E 443/4885ALDH1A1 1517/4885GAA 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.